China Medical GatewayLoading your healthcare gateway…

Liu Jia Yong

Liu Jia Yong — Chief Physician — Bone & Soft Tissue Tumor — Peking University Cancer Hospital

Specialties

1. Specialized in the standardized diagnosis and treatment and individualized therapy of soft tissue sarcomas, including the formulation of systemic treatment plans such as chemotherapy, targeted therapy, and immunotherapy. Common soft tissue sarcomas include undifferentiated pleomorphic sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, alveolar soft part sarcoma, epithelioid sarcoma, fibrosarcoma, angiosarcoma, and aggressive fibromatosis, etc.; 2. Surgical treatment of bone and soft tissue tumors; with 2 years of microsurgery training, especially skilled in the management of blood vessels and nerves during limb sarcoma resection, as well as repair and reconstruction of skin and soft tissue defects; performing over 1,000 inpatient surgeries annually (including at Nanjiao Hospital), with outpatient visits and surgeries ranking first in the department for more than ten consecutive years. 3. Surgery for malignant cutaneous melanoma.

Education

Doctor of Medicine, graduated from Peking University Health Science Center

Professional Experience

Chief Physician, Deputy Director of the Department of Bone and Soft Tissue Tumors at Peking University Cancer Hospital, Chief Physician. Focuses on precise surgical treatment and systematic medical intervention of bone and soft tissue sarcomas (emphasizing soft tissue sarcoma resection and reconstruction as well as medical treatment), particularly proficient in multidisciplinary comprehensive management of soft tissue sarcomas and individualized diagnosis and treatment of melanoma. In the treatment of soft tissue sarcomas, skilled at developing plans based on tumor pathological subtype, anatomical location, and molecular characteristics; for deep soft tissue sarcomas of the limbs and trunk, can accurately perform extensive resection combined with flap transplantation repair, effectively reducing local recurrence rates; for rare subtypes insensitive to chemotherapy, deeply explores optimization of drug treatment, leading studies on the combined application of targeted therapy and immunotherapy, and participating in randomized controlled trials of immunotherapy combined with anti-angiogenic therapy for alveolar soft part sarcoma. These related studies have received international academic attention, and his clinical practice integrates both surgical precision and medical systematization.

Professional Roles

Standing Committee Member of the Bone and Soft Tissue Tumor Branch of the China Medical Education Association; Standing Committee Member of the Bone and Soft Tissue Tumor Specialty Committee of the China Primary Health Care Foundation; Member of the Bone Tumor and Bone Metastasis Specialty Committee of the Chinese Anti-Cancer Association; Member of the CSCO Melanoma Specialty Committee; Member of the Beijing Orthopedic Professional Quality Control Expert Committee

Return to Home